Literature DB >> 1923910

Postinduction carbamazepine clearance in an adult psychiatric population.

E S Martin1, M L Crismon, P J Godley.   

Abstract

The objective of this study was to describe the postinduction clearance of carbamazepine (CBZ) in adult psychiatric patients by population pharmacokinetic analysis using the NONMEM program. Specifically, an estimate of CBZ clearance and insight into the effect of common patient characteristics on clearance were sought. Steady-state trough CBZ serum concentrations, CBZ dosing history, concomitant drug administration, and other data from 45 patients were collected retrospectively. A one-compartment model with first-order absorption and first-order elimination was used, with absorption rate, bioavailability, and volume of distribution fixed to literature values. No evidence was found that race, sex, age, ethanol use, smoking, and concomitant lithium significantly affected CBZ clearance. In the final model, clearance was based on lean body weight. The coefficient of variation for clearance estimates was 16.5%. Residual variability was modest. Estimates for volume of distribution, rates of absorption and elimination, and bioavailability could not be pursued rigorously. Although these results may assist in understanding CBZ disposition in this population, their general clinical application should be approached with caution.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923910

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

1.  Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.

Authors:  Jae Eun Ahn; Angela K Birnbaum; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

2.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

Authors:  J R Wade; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

3.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

Review 4.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Population pharmacokinetics of carbamazepine in Singapore epileptic patients.

Authors:  E Chan; H S Lee; S S Hue
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 6.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

7.  Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.

Authors:  Ghada F Ahmed; Richard C Brundage; Susan E Marino; James C Cloyd; Ilo E Leppik; Page B Pennell; R Eugene Ramsay; Angela K Birnbaum
Journal:  J Clin Pharmacol       Date:  2013-02-13       Impact factor: 3.126

Review 8.  Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Authors:  D J Morgan; K M Bray
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.